FAUC 213, a highly selective dopamine D₄ receptor full antagonist, exhibits atypical antipsychotic properties in behavioural and neurochemical models of schizophrenia

Keyphrases

• Atypical Antipsychotics 100%
• Schizophrenia Models 100%
• Neurochemicals 100%
• Amphetamine 100%
• Apomorphine 100%
• Catalepsy 100%
• Highly Selective 100%
• High-performance Liquid Chromatography 100%
• Dopamine Turnover 100%
• DRD4 100%
• Brain Regions 50%
• A1 Receptor 50%
• Antipsychotics 50%
• Dopamine 50%
• Nucleus Accumbens 50%
• Medial Prefrontal Cortex (mPFC) 50%
• Prepulse Inhibition 50%
• Locomotor Activity 50%
• Extrapyramidal Side Effects 50%
• Dorsal Striatum 50%
• D2 Receptor 50%
• Hyperlocomotion 50%
• Receptor Subtypes 50%
• Application Scheduling 50%
• Chlorophenyl 50%
• Mitogenesis 50%
• 5-HT2 Receptor 50%
• Selective Antagonist 50%
• Pharmacokinetic Study 50%
• Pyridine 50%
• Pre-pulse 50%
• Receptor Antagonism 50%
• Neurochemistry 50%
• Pyrazolo 50%
• Behavioral Neurophysiology 50%
• Dopamine Detection 50%

Neuroscience

• Atypical Antipsychotic 100%
• Apomorphine 100%
• Catalepsy 100%
• Dopamine Receptor D4 100%
• Amphetamine 100%
• Receptor 100%
• Prefrontal Cortex 50%
• Prepulse Inhibition 50%
• Nucleus Accumbens 50%
• Locomotor Activity 50%
• Hyperactivity 50%
• Extrapyramidal Symptoms 50%
• Dorsal Striatum 50%
• Piperazine 50%
• Receptor Subtype 50%
• Neuroscience 50%
• Mitogenesis 50%
• Neurochemistry 50%
• Pharmacokinetic 50%
• Antipsychotic 50%

Pharmacology, Toxicology and Pharmaceutical Science

• High Performance Liquid Chromatography 100%
• Atypical Antipsychotics 100%
• Catalepsy 100%
• Receptor 100%
• Apomorphine 100%
• Dopamine 4 Receptor 100%
• Amphetamine 100%
• Antipsychotic 50%
• Extrapyramidal Symptoms 50%
• Hyperactivity 50%
• Piperazine 50%
• Receptor Subtype 50%
• Bioavailability 50%
• Pharmacokinetics 50%